Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Infliximab (Remicade; Janssen Biotech Inc.) for first-line treatment of pediatric Crohn disease. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Infliximab (IFX) (Remicade; Janssen Biotech Inc.) is a recombinant chimeric human-murine immunoglobulin G1 monoclonal antibody designed to target and block tumor necrosis factor-alpha (TNF-?) and, thereby, reduce inflammation and associated sequelae. For pediatric Crohn disease (CD), IFX is administered by intravenous infusion in an outpatient setting at weeks 0, 2, 6, and every 8 weeks thereafter. The role of IFX in pediatric CD primarily has been as a second-line, or step-up, approach after conventional CD drugs have failed. Suggested potential benefit from first-line IFX treatment for adult CD has led to the investigation of IFX as initial, or top-down, treatment for pediatric CD, with the goal of altering its natural history.
Patient Population: IFX is a tumor necrosis factor blocker indicated for reducing signs and symptoms and
inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. IFX has not been studied in children aged < 6 years. Patient selection criteria have not been established for its use as first-line treatment for pediatric CD. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Child; Crohn Disease; Gastrointestinal Agents; Humans; Infliximab Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000958 Date abstract record published 30/08/2016 |